Undervalued Biotech Stocks Shine: Pfizer and BioNTech Show Resilience
In the ever-evolving world of the stock market, uncovering potential gold mines is paramount for smart investing. One promising area to consider is undervalued biotech stocks.
German court suspends mRNA patent trial against BioNTech
A German court on Thursday suspended a patent trial against BioNTech over the use of mRNA technology in the COVID-19 vaccine developed by the German company together with its U.S. partner Pfizer.
With New COVID-19 Boosters in Tow, Which Is the Better Buy: Pfizer, BioNtech, or Moderna Stock?
Facing significant patent cliffs, Pfizer is putting faith in new launches. Moderna has nearly doubled its pipeline in three years.
BioNTech partners with CEPI to advance development of mpox vaccine
Germany's BioNtech said on Monday it is entering into a partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of its mpox vaccine.
FDA Approves Pfizer & Moderna's New COVID Booster Vaccines
Pfizer (PFE)/ BioNTech (BNTX), and Moderna's (MRNA) updated mRNA vaccines are now approved for individuals 12 years of age and older and are authorized under emergency use for individuals 6 months ...
FDA Approves New Covid Vaccines To Target Latest Strains
The updated booster shots arrive as new coronavirus variants circulate.
US FDA authorizes updated COVID vaccines
The U.S. health regulator on Monday authorized updated COVID-19 vaccines that closely match the Omicron variants that are circulating, starting the process to deploy the shots this month.
UK joins EU in approving XBB.1.5 jab from Pfizer-BioNTech, but others subvariants are emerging
An updated Covid-19 vaccine made by Pfizer Inc (NYSE:PFE) and BioNTech has been approved by the UK medical regulator, amid a rise in new variants and subvariants of the virus. The new Pfizer-BioNTe...
UK regulator approves updated Pfizer-BioNTech COVID vaccine
The UK drug regulator said on Tuesday it has approved an updated COVID-19 vaccine by Pfizer and its German partner BioNTech that targets only the Omicron XBB.1.5 subvariant.
BioNTech: Not Just Another Jab In The Arm
BioNTech's Q2 2023 revenues significantly decreased due to declining COVID-19 vaccine sales, but the company holds $15.3B in cash reserves. The company's pipeline includes COVID-19 vaccine developm...
Pfizer, BioNTech updated COVID vaccine to treat new variants gets CHMP recommendation use in Europe
Pfizer Inc. PFE, -0.25% and BioNTech SE BNTX, +0.58% said Wednesday that its updated COVID-19 vaccine, which is tailored to the new Omicron XBB.1.5 variant has been recommended to receive marketing...
Covid Hospitalizations Jump. So Could Vaccine Demand.
Drugmakers like Pfizer and Moderna tamped down expectations. Now, cases are increasing.
U.S. Govt to Urge Citizens to Get New COVID-19 Shots
Shares of COVID-19 vaccine makers soared after reports suggest that the Biden administration will start a campaign urging citizens to vaccinate themselves with updated shots vaccine in the upcoming...
Why Moderna, BioNTech SE, and Novavax Surged Today
Last week, Moderna and BioNTech partner Pfizer said their new COVID vaccines work against the current dominant strain of omicron growing across the U.S. Today, the Biden administration announced a ...
Covid vaccine stocks jump as new variants emerge ahead of fall shot rollout
Novavax, Moderna, Pfizer and its partner BioNTech are slated to roll out new shots designed to target the omicron subvariant XBB.1.5 this fall.
Related Companies